The use of breast imaging for predicting response to neoadjuvant lapatinib, trastuzumab and their combination in HER2-positive breast cancer: Results from Neo-ALTTO

S. Di Cosimo, C. Campbell, H. A. Azim, G. Galli, G. Bregni, G. Curigliano, C. Criscitiello, M. Izquierdo, L. de la Pena, D. Fumagalli, L. Fein, J. Vinholes, W. M.J. Ng, M. Colleoni, A. Ferro, B. J. Naume, A. Patel, J. Huober, M. J. Piccart-Gebhart, J. BaselgaE. de Azambuja

Research output: Contribution to journalArticle

Abstract

Aim To determine the value of mammography and breast ultrasound (US) in predicting outcomes in HER2 positive breast cancer patients (pts) within Neo-ALTTO trial. Patients and methods Mammography and US were required at baseline, week 6 and surgery. Two independent blinded investigators reviewed the measurements and assigned the corresponding response category. Pts showing complete or partial response according to RECIST (v1.1) were classified as responders. The association between imaging response at week 6 or prior to surgery was evaluated with respect to pathological complete response (pCR) and event-free Survival (EFS). Results Of the 455 pts enrolled in the trial, 267 (61%) and 340 (77%) had evaluable mammography and US at week 6; 248 (56%) and 309 (70%) pts had evaluable mammography and US prior to surgery. At week 6, 32% and 43% of pts were classified as responders by mammography and US, respectively. pCR rates were twice as high for responders than non-responders (week 6: 46% versus 23% by US, p < 0.0001; 41% versus 24% by mammography, p = 0.007). Positive and negative predictive values of mammography and US prior to surgery were 37% and 35%, and 82% and 70%, respectively. No significant correlation was found between response by mammography and/or US at week 6/surgery and EFS. Conclusions Mammography and US were underused in Neo-ALTTO although US had the potential to assess early response whereas mammography to detect residual disease prior to surgery. Our data still emphasise the need for further imaging studies on pts treated with neoadjuvant HER2-targeted therapy.

Original languageEnglish
Pages (from-to)42-48
Number of pages7
JournalEuropean Journal of Cancer
Volume89
DOIs
Publication statusPublished - Jan 1 2018

Fingerprint

Mammary Ultrasonography
Breast
Breast Neoplasms
Mammography
Disease-Free Survival
lapatinib
Trastuzumab
Research Personnel

Keywords

  • Breast ultrasound
  • HER2 positive breast cancer
  • Mammography
  • Neoadjuvant
  • Targeted therapy

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

The use of breast imaging for predicting response to neoadjuvant lapatinib, trastuzumab and their combination in HER2-positive breast cancer : Results from Neo-ALTTO. / Di Cosimo, S.; Campbell, C.; Azim, H. A.; Galli, G.; Bregni, G.; Curigliano, G.; Criscitiello, C.; Izquierdo, M.; de la Pena, L.; Fumagalli, D.; Fein, L.; Vinholes, J.; Ng, W. M.J.; Colleoni, M.; Ferro, A.; Naume, B. J.; Patel, A.; Huober, J.; Piccart-Gebhart, M. J.; Baselga, J.; de Azambuja, E.

In: European Journal of Cancer, Vol. 89, 01.01.2018, p. 42-48.

Research output: Contribution to journalArticle

Di Cosimo, S, Campbell, C, Azim, HA, Galli, G, Bregni, G, Curigliano, G, Criscitiello, C, Izquierdo, M, de la Pena, L, Fumagalli, D, Fein, L, Vinholes, J, Ng, WMJ, Colleoni, M, Ferro, A, Naume, BJ, Patel, A, Huober, J, Piccart-Gebhart, MJ, Baselga, J & de Azambuja, E 2018, 'The use of breast imaging for predicting response to neoadjuvant lapatinib, trastuzumab and their combination in HER2-positive breast cancer: Results from Neo-ALTTO', European Journal of Cancer, vol. 89, pp. 42-48. https://doi.org/10.1016/j.ejca.2017.10.036
Di Cosimo, S. ; Campbell, C. ; Azim, H. A. ; Galli, G. ; Bregni, G. ; Curigliano, G. ; Criscitiello, C. ; Izquierdo, M. ; de la Pena, L. ; Fumagalli, D. ; Fein, L. ; Vinholes, J. ; Ng, W. M.J. ; Colleoni, M. ; Ferro, A. ; Naume, B. J. ; Patel, A. ; Huober, J. ; Piccart-Gebhart, M. J. ; Baselga, J. ; de Azambuja, E. / The use of breast imaging for predicting response to neoadjuvant lapatinib, trastuzumab and their combination in HER2-positive breast cancer : Results from Neo-ALTTO. In: European Journal of Cancer. 2018 ; Vol. 89. pp. 42-48.
@article{101cf6f6655a4f7ba10197249880cdab,
title = "The use of breast imaging for predicting response to neoadjuvant lapatinib, trastuzumab and their combination in HER2-positive breast cancer: Results from Neo-ALTTO",
abstract = "Aim To determine the value of mammography and breast ultrasound (US) in predicting outcomes in HER2 positive breast cancer patients (pts) within Neo-ALTTO trial. Patients and methods Mammography and US were required at baseline, week 6 and surgery. Two independent blinded investigators reviewed the measurements and assigned the corresponding response category. Pts showing complete or partial response according to RECIST (v1.1) were classified as responders. The association between imaging response at week 6 or prior to surgery was evaluated with respect to pathological complete response (pCR) and event-free Survival (EFS). Results Of the 455 pts enrolled in the trial, 267 (61{\%}) and 340 (77{\%}) had evaluable mammography and US at week 6; 248 (56{\%}) and 309 (70{\%}) pts had evaluable mammography and US prior to surgery. At week 6, 32{\%} and 43{\%} of pts were classified as responders by mammography and US, respectively. pCR rates were twice as high for responders than non-responders (week 6: 46{\%} versus 23{\%} by US, p < 0.0001; 41{\%} versus 24{\%} by mammography, p = 0.007). Positive and negative predictive values of mammography and US prior to surgery were 37{\%} and 35{\%}, and 82{\%} and 70{\%}, respectively. No significant correlation was found between response by mammography and/or US at week 6/surgery and EFS. Conclusions Mammography and US were underused in Neo-ALTTO although US had the potential to assess early response whereas mammography to detect residual disease prior to surgery. Our data still emphasise the need for further imaging studies on pts treated with neoadjuvant HER2-targeted therapy.",
keywords = "Breast ultrasound, HER2 positive breast cancer, Mammography, Neoadjuvant, Targeted therapy",
author = "{Di Cosimo}, S. and C. Campbell and Azim, {H. A.} and G. Galli and G. Bregni and G. Curigliano and C. Criscitiello and M. Izquierdo and {de la Pena}, L. and D. Fumagalli and L. Fein and J. Vinholes and Ng, {W. M.J.} and M. Colleoni and A. Ferro and Naume, {B. J.} and A. Patel and J. Huober and Piccart-Gebhart, {M. J.} and J. Baselga and {de Azambuja}, E.",
year = "2018",
month = "1",
day = "1",
doi = "10.1016/j.ejca.2017.10.036",
language = "English",
volume = "89",
pages = "42--48",
journal = "European Journal of Cancer",
issn = "0959-8049",
publisher = "Elsevier Ltd",

}

TY - JOUR

T1 - The use of breast imaging for predicting response to neoadjuvant lapatinib, trastuzumab and their combination in HER2-positive breast cancer

T2 - Results from Neo-ALTTO

AU - Di Cosimo, S.

AU - Campbell, C.

AU - Azim, H. A.

AU - Galli, G.

AU - Bregni, G.

AU - Curigliano, G.

AU - Criscitiello, C.

AU - Izquierdo, M.

AU - de la Pena, L.

AU - Fumagalli, D.

AU - Fein, L.

AU - Vinholes, J.

AU - Ng, W. M.J.

AU - Colleoni, M.

AU - Ferro, A.

AU - Naume, B. J.

AU - Patel, A.

AU - Huober, J.

AU - Piccart-Gebhart, M. J.

AU - Baselga, J.

AU - de Azambuja, E.

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Aim To determine the value of mammography and breast ultrasound (US) in predicting outcomes in HER2 positive breast cancer patients (pts) within Neo-ALTTO trial. Patients and methods Mammography and US were required at baseline, week 6 and surgery. Two independent blinded investigators reviewed the measurements and assigned the corresponding response category. Pts showing complete or partial response according to RECIST (v1.1) were classified as responders. The association between imaging response at week 6 or prior to surgery was evaluated with respect to pathological complete response (pCR) and event-free Survival (EFS). Results Of the 455 pts enrolled in the trial, 267 (61%) and 340 (77%) had evaluable mammography and US at week 6; 248 (56%) and 309 (70%) pts had evaluable mammography and US prior to surgery. At week 6, 32% and 43% of pts were classified as responders by mammography and US, respectively. pCR rates were twice as high for responders than non-responders (week 6: 46% versus 23% by US, p < 0.0001; 41% versus 24% by mammography, p = 0.007). Positive and negative predictive values of mammography and US prior to surgery were 37% and 35%, and 82% and 70%, respectively. No significant correlation was found between response by mammography and/or US at week 6/surgery and EFS. Conclusions Mammography and US were underused in Neo-ALTTO although US had the potential to assess early response whereas mammography to detect residual disease prior to surgery. Our data still emphasise the need for further imaging studies on pts treated with neoadjuvant HER2-targeted therapy.

AB - Aim To determine the value of mammography and breast ultrasound (US) in predicting outcomes in HER2 positive breast cancer patients (pts) within Neo-ALTTO trial. Patients and methods Mammography and US were required at baseline, week 6 and surgery. Two independent blinded investigators reviewed the measurements and assigned the corresponding response category. Pts showing complete or partial response according to RECIST (v1.1) were classified as responders. The association between imaging response at week 6 or prior to surgery was evaluated with respect to pathological complete response (pCR) and event-free Survival (EFS). Results Of the 455 pts enrolled in the trial, 267 (61%) and 340 (77%) had evaluable mammography and US at week 6; 248 (56%) and 309 (70%) pts had evaluable mammography and US prior to surgery. At week 6, 32% and 43% of pts were classified as responders by mammography and US, respectively. pCR rates were twice as high for responders than non-responders (week 6: 46% versus 23% by US, p < 0.0001; 41% versus 24% by mammography, p = 0.007). Positive and negative predictive values of mammography and US prior to surgery were 37% and 35%, and 82% and 70%, respectively. No significant correlation was found between response by mammography and/or US at week 6/surgery and EFS. Conclusions Mammography and US were underused in Neo-ALTTO although US had the potential to assess early response whereas mammography to detect residual disease prior to surgery. Our data still emphasise the need for further imaging studies on pts treated with neoadjuvant HER2-targeted therapy.

KW - Breast ultrasound

KW - HER2 positive breast cancer

KW - Mammography

KW - Neoadjuvant

KW - Targeted therapy

UR - http://www.scopus.com/inward/record.url?scp=85038836808&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85038836808&partnerID=8YFLogxK

U2 - 10.1016/j.ejca.2017.10.036

DO - 10.1016/j.ejca.2017.10.036

M3 - Article

C2 - 29227816

AN - SCOPUS:85038836808

VL - 89

SP - 42

EP - 48

JO - European Journal of Cancer

JF - European Journal of Cancer

SN - 0959-8049

ER -